Cargando…

Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis

SIMPLE SUMMARY: The study showed that androgen deprivation therapy for a preceding diagnosis of prostate cancer is associated with prolonged survival among patients who subsequently develop lung cancer. These population-level findings support a role of the androgen receptor in lung cancer. ABSTRACT:...

Descripción completa

Detalles Bibliográficos
Autores principales: Nazha, Bassel, Zhang, Chao, Chen, Zhengjia, Ragin, Camille, Owonikoko, Taofeek K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265064/
https://www.ncbi.nlm.nih.gov/pubmed/35804979
http://dx.doi.org/10.3390/cancers14133206
_version_ 1784743118438924288
author Nazha, Bassel
Zhang, Chao
Chen, Zhengjia
Ragin, Camille
Owonikoko, Taofeek K.
author_facet Nazha, Bassel
Zhang, Chao
Chen, Zhengjia
Ragin, Camille
Owonikoko, Taofeek K.
author_sort Nazha, Bassel
collection PubMed
description SIMPLE SUMMARY: The study showed that androgen deprivation therapy for a preceding diagnosis of prostate cancer is associated with prolonged survival among patients who subsequently develop lung cancer. These population-level findings support a role of the androgen receptor in lung cancer. ABSTRACT: Introduction: The crosstalk between receptor kinase signaling, such as EGFR and androgen receptor signaling, suggests a potential interaction between androgen deprivation therapy (ADT) and lung cancer outcome. Methods: We employed the SEER–Medicare data of lung cancer patients diagnosed between 1988 and 2005 to test for an association between ADT for prostate cancer and lung cancer outcome. We employed the Kaplan–Meier method and Cox proportional hazard with log-rank test model to assess any significant impact of ADT on survival. Results: We included data from 367,750 lung cancer patients; 17.4%, 2.9%, 33.6% and 46.1% with stages I, II, III and IV, respectively; 84.5% were >65 years; 57.2% males; 84.2% Caucasians and 9.3% Blacks. There were 11,061 patients (3%) with an initial prostate cancer diagnosis followed by lung cancer (P-L group); 3017 (0.8%) with an initial diagnosis of lung cancer and subsequent prostate cancer diagnosis (L-P group); the remainder had only lung cancer (L group). Stage I lung cancer was most common in the L-P group compared to the L and P-L groups—54% vs. 17.13% vs. 17.92%, p < 0.0001 for L-P, L and P-L, respectively. The median OS for lung cancer diagnosis was 93 months versus 10 and 9 months, respectively, for the L-P, L and P-L subgroups. ADT was associated with improved survival on multivariate analysis, especially in Caucasian patients (HR of death: 0.86; 95% CI: 0.76–0.97; p = 0.012). Conclusion: ADT was associated with improved outcome for NSCLC, in line with the hypothesis of a role for the androgen receptor in lung cancer. Our findings support a systematic evaluation of the potential benefit of ADT as a therapy for lung cancer.
format Online
Article
Text
id pubmed-9265064
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92650642022-07-09 Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis Nazha, Bassel Zhang, Chao Chen, Zhengjia Ragin, Camille Owonikoko, Taofeek K. Cancers (Basel) Article SIMPLE SUMMARY: The study showed that androgen deprivation therapy for a preceding diagnosis of prostate cancer is associated with prolonged survival among patients who subsequently develop lung cancer. These population-level findings support a role of the androgen receptor in lung cancer. ABSTRACT: Introduction: The crosstalk between receptor kinase signaling, such as EGFR and androgen receptor signaling, suggests a potential interaction between androgen deprivation therapy (ADT) and lung cancer outcome. Methods: We employed the SEER–Medicare data of lung cancer patients diagnosed between 1988 and 2005 to test for an association between ADT for prostate cancer and lung cancer outcome. We employed the Kaplan–Meier method and Cox proportional hazard with log-rank test model to assess any significant impact of ADT on survival. Results: We included data from 367,750 lung cancer patients; 17.4%, 2.9%, 33.6% and 46.1% with stages I, II, III and IV, respectively; 84.5% were >65 years; 57.2% males; 84.2% Caucasians and 9.3% Blacks. There were 11,061 patients (3%) with an initial prostate cancer diagnosis followed by lung cancer (P-L group); 3017 (0.8%) with an initial diagnosis of lung cancer and subsequent prostate cancer diagnosis (L-P group); the remainder had only lung cancer (L group). Stage I lung cancer was most common in the L-P group compared to the L and P-L groups—54% vs. 17.13% vs. 17.92%, p < 0.0001 for L-P, L and P-L, respectively. The median OS for lung cancer diagnosis was 93 months versus 10 and 9 months, respectively, for the L-P, L and P-L subgroups. ADT was associated with improved survival on multivariate analysis, especially in Caucasian patients (HR of death: 0.86; 95% CI: 0.76–0.97; p = 0.012). Conclusion: ADT was associated with improved outcome for NSCLC, in line with the hypothesis of a role for the androgen receptor in lung cancer. Our findings support a systematic evaluation of the potential benefit of ADT as a therapy for lung cancer. MDPI 2022-06-30 /pmc/articles/PMC9265064/ /pubmed/35804979 http://dx.doi.org/10.3390/cancers14133206 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nazha, Bassel
Zhang, Chao
Chen, Zhengjia
Ragin, Camille
Owonikoko, Taofeek K.
Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
title Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
title_full Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
title_fullStr Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
title_full_unstemmed Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
title_short Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER–Medicare Database Analysis
title_sort concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: a seer–medicare database analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265064/
https://www.ncbi.nlm.nih.gov/pubmed/35804979
http://dx.doi.org/10.3390/cancers14133206
work_keys_str_mv AT nazhabassel concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis
AT zhangchao concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis
AT chenzhengjia concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis
AT ragincamille concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis
AT owonikokotaofeekk concurrentandrogendeprivationtherapyforprostatecancerimprovessurvivalforsynchronousormetachronousnonsmallcelllungcanceraseermedicaredatabaseanalysis